The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. Read Healio’s ...

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...